Home LiteratureArticle Details
PMID: 26447188 Published · ppublish English Letter Research Support, Non-U.S. Gov't

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Blood ·Vol. 126 ·No. 24 ·2015-12-10 ·Pages 2646-9

Freeman CL, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T, Fingerle-Rowson G, Wassner-Fritsch E, Gribben JG, Hallek M, Salles G, Cartron G

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal, Humanized/administration & dosage,adverse effects,pharmacology,therapeutic use Antineoplastic Agents/administration & dosage,adverse effects,pharmacology,therapeutic use B-Lymphocytes/drug effects Capillary Leak Syndrome/chemically induced Clinical Trials, Phase I as Topic/statistics & numerical data Clinical Trials, Phase II as Topic/statistics & numerical data Cytokines/metabolism Edema/chemically induced Humans Hypotension/chemically induced Hypoxia/chemically induced Infusions, Intravenous Interleukin-6/metabolism Interleukin-8/metabolism Killer Cells, Natural/immunology Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy,physiopathology Lymphocyte Depletion Multicenter Studies as Topic/statistics & numerical data Syndrome
Chemicals
Antibodies, Monoclonal, Humanized Antineoplastic Agents CXCL8 protein, human Cytokines IL6 protein, human Interleukin-6 Interleukin-8 obinutuzumab
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Freeman Ciara L ORCID
Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, United Kingdom.
Morschhauser Franck
Hematology, Centre Hospitalier Régional Universitaire de Lille, Unité Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA), Université de Lille, Lille, France.
Sehn Laurie
Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada.
Dixon Mark
Department of Biostatistics and Department of Statistical Programming and Analysis, Roche Products Limited, Welwyn Garden City, United Kingdom.
Houghton Richard
Department of Biostatistics and Department of Statistical Programming and Analysis, Roche Products Limited, Welwyn Garden City, United Kingdom.
Lamy Thierry
Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.
Fingerle-Rowson Günter
Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Wassner-Fritsch Elisabeth
Pharma Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Gribben John G
Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, United Kingdom.
Hallek Michael
Department of Internal Medicine, Center of Integrated Oncology & Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases (CECAD), University of Cologne, Cologne, Germany.
Salles Gilles
Hospices Civils de Lyon, Université Claude Bernard, Lyon, France.
Cartron Guillaume
Department of Clinical Hematology, Centre Hospitalier Régional Universitaire, Université de Montpellier, Montpellier, France.
References (22)
22 references, click to expand
  1. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Blood. 2010 Jun 3;115(22):4393-402 PMID: 20194898
  2. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Br J Haematol. 2011 Feb;152(3):295-306 PMID: 21155758
  3. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Clin Sci (Lond). 2012 Feb;122(4):143-59 PMID: 22029668
  4. Interleukin-6 in sepsis and capillary leakage syndrome.
    J Interferon Cytokine Res. 2012 Feb;32(2):60-5 PMID: 22136372
  5. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.
    Blood. 2012 May 31;119(22):5118-25 PMID: 22438256
  6. Rituximab-induced thrombocytopenia: a cohort study.
    Eur J Haematol. 2012 Sep;89(3):256-66 PMID: 22639923
  7. Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.
    Leuk Res. 2013 Apr;37(4):440-6 PMID: 23259986
  8. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.
    J Clin Oncol. 2001 Apr 15;19(8):2153-64 PMID: 11304767
  9. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.
    Clin Cancer Res. 2003 Oct 15;9(13):4653-65 PMID: 14581334
  10. Modulation of cytokine-induced production of IL-8 in vitro by interferons and glucocorticosteroids.
    Inflammation. 2004 Apr;28(2):77-88 PMID: 15379213
  11. [Ca2+]i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/MGSA.
    J Leukoc Biol. 1991 Sep;50(3):279-86 PMID: 1856598
  12. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
    Blood. 1995 Jun 1;85(11):3066-76 PMID: 7538815
  13. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway.
    Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14196-201 PMID: 9826677
  14. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.
    J Clin Oncol. 1999 Mar;17(3):791-5 PMID: 10071268
  15. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
    Blood. 1999 Oct 1;94(7):2217-24 PMID: 10498591
  16. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis.
    Adv Ther. 2007 Jan-Feb;24(1):29-40 PMID: 17526459
  17. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
    Am J Hematol. 2009 Apr;84(4):247-50 PMID: 19260124
  18. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.
    Blood. 2013 Nov 14;122(20):3482-91 PMID: 24106207
  19. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    N Engl J Med. 2014 Mar 20;370(12):1101-10 PMID: 24401022
  20. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.
    Blood. 2014 Oct 2;124(14):2196-202 PMID: 25143487
  21. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
    Am J Hematol. 2015 May;90(5):446-60 PMID: 25908509
  22. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
    Leukemia. 2015 Jul;29(7):1602-4 PMID: 25634683
Article Info
Journal
Blood
Abbr.
Blood
ISSN
1528-0020
DOI
10.1182/blood-2015-09-670802
Published
2015-12-10
Epub
2015-00-07
Pages
2646-9
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC4671111
Subset
IM
Grants
NCI NIH HHS · P01 CA081534 · United States
External Links
PubMed source DOI: 10.1182/blood-2015-09-670802 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2